CAJ | 학술논문

目的：分析来氟米特联合白芍总苷治疗类风湿关节炎的临床疗效及不良反应。方法：选取2012年6月—2014年6月收治的100例类风湿关节炎患者，分为治疗组50例（来氟米特联合白芍总苷）和对照组50例（单用来氟米特）。观察治疗前及治疗12周后两组患者各项指标变化及不良反应。结果：治疗12周后，治疗组总有效率为94％，对照组总有效率为78％，治疗后两组患者关节肿胀数、关节压痛数、晨僵时间、疼痛视觉模拟（VAS）评分、红细胞沉降率（ESR）、C 反应蛋白（CRP）、类风湿因子（RF）指标均明显下降（P ＜0.05），且治疗组下降值较对照组更明显，差异有统计学意义（P ＜0.05）；治疗后治疗组不良反应发生率为8％，对照组不良反应发生率为26％，且对照组的肝功能损害发生率明显高于治疗组（P ＜0.05）。结论：来氟米特联合白芍总苷胶囊治疗类风湿关节炎疗效显著，不良反应较少。
목적：분석래불미특연합백작총감치료류풍습관절염적림상료효급불량반응。방법：선취2012년6월—2014년6월수치적100례류풍습관절염환자，분위치료조50례（래불미특연합백작총감）화대조조50례（단용래불미특）。관찰치료전급치료12주후량조환자각항지표변화급불량반응。결과：치료12주후，치료조총유효솔위94％，대조조총유효솔위78％，치료후량조환자관절종창수、관절압통수、신강시간、동통시각모의（VAS）평분、홍세포침강솔（ESR）、C 반응단백（CRP）、류풍습인자（RF）지표균명현하강（P ＜0.05），차치료조하강치교대조조경명현，차이유통계학의의（P ＜0.05）；치료후치료조불량반응발생솔위8％，대조조불량반응발생솔위26％，차대조조적간공능손해발생솔명현고우치료조（P ＜0.05）。결론：래불미특연합백작총감효낭치료류풍습관절염료효현저，불량반응교소。
Objective:To investigate the clinical efficacy and safety of leflunomide combine with total glucosides of paeony capsules for patients with rheumatoid arthritis. Methods:One hundred patients with rheumatoid arthritis from June 2012 to June 2014 were randomly divided into the treatment group(n = 50)and the control group(n = 50). The patients in the treatment group accepted the treatment of leflunomide and total glucosides of paeony capsules,the control group received the treatment of leflunomide only. Indicators and adverse reaction were evaluated before and after the treatment. Results:After the 12 weeks of clinical treatment,the effective rate in treatment group was 94% ,otherwise in control group was 78% ,the clinical symptoms, visual analogue scale(VAS),erythrocyte sedimentation rate(ESR),C - reactive protein(CRP),rheumatoid factor(RF)in the treatment group significantly lower than that in the control group(P < 0. 05),the rate of adverse effect in treatment group was 8% ,and 26% in control group,the liver dysfunction in control group was higher than treatment group(P < 0. 05). Conclu-sion:The effect of treating rheumatoid arthritis with leflunomide and total glucosides of paeony capsules is safe and valuable.